Type One Diabetes Completed Phase 2 Trials for Ustekinumab (DB05679)

Also known as: Diabetes Mellitus, Juvenile-Onset / T1DM - Type 1 Diabetes Mellitus / Diabetes Type I / Type I Diabetes / Type1 Diabetes / Diabetes Type One / Diabete Type 1 / Type One Diabetes Mellitus / Diabetics Mellitus Type 1 / Type 1 Diabetes / Type 1 Diabetes Mellitus (T1DM) / Insulin-Dependent Diabetes Mellitus 1 / Type1diabetes / Diabetes Mellitus Type I / Type1 Diabetes Mellitus / Type 1 Diabetes (T1D) / Diabetes Mellitus Type 1 / Juvenile Onset Diabetes Mellitus / Diabetes Type 1 / Type 1 Insulin-Dependent Diabetes Mellitus / Type I Diabetes Mellitus / Diabetes Mellitus, Sudden-Onset / Type-1 Diabetes Mellitus / Insulin Dependent Diabetes Mellitus 1 / Type 1 Diabetes Mellitus / Juvenile-Onset Diabetes / Diabetes Mellitus, Insulin-Dependent, 1 / Diabetes mellitus type 1 (disorder) / Diabetes mellitus: [juvenile] or [insulin dependent] / Juvenile diabetes / Insulin dependent diabetic / IDDM / Diabetes mellitus insulin-dependent / Insulin-dependent diabetes mellitus / Diabetes mellitus juvenile onset / Immune-mediated diabetes / Insulin dependent diabetes mellitus / Insulin dependent diabetes mel / IDDM - Insulin-dependent diabetes mellitus / Diabetes mellitus - juvenile / Ketosis-prone diabetes mellitus (disorder) / Ketosis-prone diabetes mellitus

IndicationStatusPhase
DBCOND0076728 (Type One Diabetes)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02204397
Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 MelitisTreatment